Plasma Fractionation Market

Market Overview:

The global plasma fractionation market size reached US$ 23.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 33.7 Billion by 2028, exhibiting a growth rate (CAGR) of 5.8% during 2023-2028.

Plasma fractionation refers to the downstream processing of donated plasma into life-saving therapies and medicinal products. It breaks plasma into individual proteins or plasma fractions using mechanical separation methods, such as centrifugation, depth filtration, precipitation, and chromatography. Nowadays, several modern fractionation processes use alcohol concentrations, time, temperature, and pH to extract specific therapeutic proteins. Moreover, increasing technology complexity over the years and the introduction of in-process viral reduction treatments have resulted in the development of new protein therapeutics and improvement in product purity and quality.

Plasma Fractionation Market Trends:

Protein products fractionated from human plasma are an essential class of therapeutics widely used to prevent, manage, and treat life-threatening conditions, such as infections, congenital deficiencies, rare blood disorders, immunologic disorders, and autoimmune disorders. A significant rise in the prevalence of these conditions among a significant part of the population globally represents one of the key factors impelling the market growth. In addition, manufacturers are developing plasma fractionation with additional safety features due to the implementation of stringent regulations and standard controls and settings by governing agencies of numerous countries on quality assurance of biological products. Apart from this, market players are financing research and development (R&D) activities to launch advancement in plasma production technology to improve product efficacy and enhance recovery of immunoglobulin G (IgG) to isolate new plasma proteins. Furthermore, they are focusing on developing affordable viral inactivation and processing technologies that allow utilization of local plasma resources safely. This, in confluence with the escalating need to improve yield, maintain process economics, and manage increasing regulatory requirements, is anticipated to provide a favorable market outlook in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global plasma fractionation market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, sector, application and end user.

Breakup by Product:

• Immunoglobulins
• Albumin
• Coagulation factor VIII
• Coagulation factor IX
   

Breakup by Sector:

• Private Sector
• Public Sector
   

Breakup by Application:

• Neurology
• Immunology
• Hematology
• Other Applications
   

Breakup by End User:

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited.

Report Coverage: